Cited by 410Nanoparticle-Based Drug DeliveryAdvanced Drug Delivery SystemsRNA Interference and Gene Delivery

Nanotechnology for protein delivery: Overview and perspectives

Open access
Yu, Mikyung, Wu, Jun, Shi, Jinjun, Farokhzad, Omid C.·2016·Journal of Controlled Release

Abstract

Protein-based therapeutics have made a significant impact in the treatment of a variety of important human diseases. However, given their intrinsically vulnerable structure and susceptibility to enzymatic degradation, many therapeutic proteins such as enzymes, growth factors, hormones, and cytokines suffer from poor physicochemical/biological stability and immunogenicity that may limit their potential benefits, and in some cases limit their utility. Furthermore, when protein therapeutics are developed for intracellular targets, their internalization and biological activity may be limited by inefficient membrane permeability and/or endosomal escape. Development of effective protein delivery strategies is therefore essential to further enhance therapeutic outcomes to enable widespread medical applications. This review discusses the advantages and limitations of marketed and developmental-stage protein delivery strategies, and provides a focused overview of recent advances in nanotechnology platforms for the systemic delivery of therapeutic proteins. In addition, we also highlight nanoparticle-mediated non-invasive administration approaches (e.g., oral, nasal, pulmonary, and transdermal routes) for protein delivery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2015.10.012

Cites

138 of 138 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Delivery of proteins such as catalase raises concerns of instability in vivo due to physiological proteases, unpredictable protein immunogenicity, and poor in vivo half-life.

    “Delivery of proteins such as catalase raises a few concerns such as its instability in vivo due to the presence of numerous physiological proteases, unpredictable protein immunogenicity, and poor in vivo half-life.27,28”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [18]Sassi AB Nagarkar R Hamblin P Novel Approaches and Strategies for Biologics Singh M Salnikova M Vaccines and Cancer Therapies Elsevier Inc 2015 199 217
  2. [133]Nose K Pissuwan D Goto M Katayama Y Niidome T Gold nanorods in an oil-base formulation for transdermal treatment of type 1 diabetes in mice Nanoscale 4 2012 3776 3780 22622618

Cited by

Sorted by citations

Authors
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
  • Shi, Jinjun
  • Farokhzad, Omid C.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2016-10
Volume
240
Pages
24-37
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2173147935
Cited by
410
References
138
Citations by year
2026: 29 · 2025: 47 · 2024: 34 · 2023: 40 · 2022: 44 · 2021: 65 · 2020: 47 · 2019: 48 · 2018: 26 · 2017: 21 · 2016: 9
FWCI
1.13
Type
journal article
Language
en
Open access
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
Funders
  • National Institutes of Health (NIH) (EB015419, R00CA160350, U54-CA151884)
  • Movember-Prostate Cancer Foundation (PCF)
  • National Research Foundation of Korea (K1A1A2048701)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
protein delivery, nanotechnology, therapeutic proteins, nanoparticle drug delivery, systemic drug delivery, intracellular delivery, endosomal escape, membrane permeability, protein stability, immunogenicity, oral drug delivery, intranasal drug delivery, pulmonary drug delivery, transdermal drug delivery
MeSH terms
Animals, Humans, Proteins, Tissue Distribution, Drug Delivery Systems, Nanotechnology, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review